Cigna sues Bristol Myers for alleged monopoly over blockbuster cancer drug

Cigna has filed an antitrust lawsuit against Bristol Myers Squibb (BMS), alleging the drugmaker illegally maintained a monopoly on its blockbuster blood cancer drug Pomalyst, which generated $2.7 billion in U.S. sales last year. Cigna claims BMS's Celgene unit used sham lawsuits, paid off generic drugmakers, and defrauded the U.S. Patent and Trademark Office to prevent generic competition, causing purchasers to overpay by potentially billions of dollars. This action follows a recent dismissal of a similar class-action claim against BMS, where a federal judge found insufficient evidence of fraud or baseless lawsuits.

Analysis

Bristol Myers Squibb (BMY) is facing a significant legal and financial challenge following an antitrust lawsuit filed by Cigna (CI). The lawsuit alleges that BMY's Celgene unit illegally suppressed generic competition for its blockbuster blood cancer drug, Pomalyst, which generated $2.7 billion in U.S. sales last year and $537 million in the first three months of 2025. Cigna's claims center on sham patent litigation and pay-for-delay schemes, which it argues forced purchasers to overpay by potentially billions of dollars. This legal action introduces substantial headline risk and potential financial liability for BMY, reflected in the strongly negative sentiment signal (-0.8). However, a critical mitigating factor is the recent dismissal of a similar class-action suit, where a federal judge found insufficient evidence of fraud or baseless litigation by Celgene. This prior ruling could present a significant legal hurdle for Cigna's case and may temper the long-term market impact.

Key Decisions for Investors

• Investors in Bristol Myers Squibb should monitor this litigation closely, as a negative outcome could jeopardize the significant revenue from Pomalyst and lead to substantial damages, justifying the stock's negative sentiment.
• The recent dismissal of a similar lawsuit against BMY provides a key legal precedent that may limit the ultimate financial risk, suggesting the market's initial reaction could be over-stated pending further legal developments.
• For Cigna investors, the lawsuit presents a potential long-term catalyst for a large financial recovery, but its success is highly uncertain given it must overcome the legal arguments that led to the failure of the previous case.
• This case serves as a critical indicator of the ongoing legal and pricing battles between pharmaceutical manufacturers and insurance payers over patent exclusivity and drug costs, with potential read-throughs for the broader healthcare sector.